NCE-1 Intelligence & Market Opportunity

Cosela

Trilacicilib

Chemoprotective agent

Intravenous Powder

Approval Date

02-Dec-21

NCE-1 Date

02-Dec-25

NCE Date

02-Dec-26

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Trilacicilib

Innovator

G1 THERAPEUTICS, INC.

Dosage Form

Intravenous Powder

Strength

EQ 300 mg base/vial

Therapeutic Category

Chemoprotective agent

Usage

To mitigate chemotherapy-induced myelosuppression in small cell lung cancer

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.